Weekly Immune Digest
As an introduction to this new topic on our website, we will select relevant articles in the immunotherapy and immune-biomarker field, just for your interest and on a weekly basis.
If you want us to add here your achievement in these domains, just email us and Philip Beer with one sentence on your manuscript and the correct reference.
At your service!
- A window study in ovarian cancer sheds light on the failure of IDO1 inhibitors in clinical trials: metabolic rewiring of the immune microenvironment in IDO1 inhibitor exposed tumours resulted in bypass suppression of T cell activity.
- The US-based NCI-MATCH study has opened a new arm to study combined inhibition of PD-1 and LAG-3 in patients with microsatellite unstable tumours who have failed anti-PD-(L)1 therapy.
- The FDA have approved combined PD-1/LAG-3 inhibition in advanced melanoma, based on improved PFS versus PD-1 inhibition alone in the RELATIVITY-047 phase 3 trial.
- European regulator CHMP has taken a more conservation view than the FDA to pembrolizumab (anti-PD1) in microsatellite unstable disease, restricting its recommendation to MSI+ colorectal, endometrial, gastric, small bowel & biliary cancers.
- A new study based on five melanoma cohorts uncovers complexity in the role of the gut microbiome in predicting response to immune checkpoint inhibition, with cohort-dependent effects complicating response prediction.
Overview Articles
Natural killer cells are a type of lymphocytes which destroy cancer cells and other altered cells releasing cytotoxic granules.
